5-(6-methylamino-pyrimidin-4-yloxy)-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amide | 882405-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(6-methylamino-pyrimidin-4-yloxy)-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amide
• 英文别名: N-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-5-[6-(methylamino)pyrimidin-4-yl]oxy-2,3-dihydroindole-1-carboxamide
• CAS: 882405-22-3
• 化学式: C₂₇H₃₃N₇O₂
• 分子量: 487.605
• InChiKey: BYIDRWJHCXIPLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  85.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amide 、 甲胺 以 四氢呋喃 为溶剂， 反应 72.0h， 生成 5-(6-methylamino-pyrimidin-4-yloxy)-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amide
  参考文献：
  名称：

  Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors

  摘要：

  本发明涉及公式I的新化合物：其中p为1、2或3；n为0、1、2或3；m为0、1、2或3；A为CRc、S、NRcor O，其中Rcis H或较低的烷基；X、Y和Z各自独立地选择自N或C—R3，其中至少有两个X、Y和Z为N；而每个Rais独立选择自氢和较低的烷基；每个Rbis氢或较低的烷基；G是Ar基团或表示CN或未取代或取代的较低烷基；Ar是饱和或不饱和的环状基团，其被取代或未取代，并且可能是五元或六元的单环或8、9、10、11或12元的双环或三环，并且可能包含0、1、2或3个从O、N和S中选择的杂原子；其中基团具有R1、R2、R3和R4的含义如本文所定义，其盐、酯、N-氧化物或前药；并且它们在蛋白激酶依赖性疾病的治疗中的使用，它们在制造用于治疗该等疾病的药物组合物中的使用，二苯基脲衍生物在治疗该等疾病中的使用方法，包括这些新的二苯基脲衍生物的制药制剂，制造新的二苯基脲衍生物的方法，上述提到的新的二苯基脲衍生物的使用或使用方法，以及/或这些新的二苯基脲衍生物用于治疗动物或人体。

  公开号：

  US20080039440A1

文献信息

• [EN] CYCLIC DIARLY UREAS SUITABLE AS TYROSINE KINASE INHIBITORS<br/>[FR] UREES DIARYLE CYCLIQUES EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2006034833A1

  公开（公告）日：2006-04-06

  The invention relates to novel compounds of Formula (I): wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; mis0,1,2or3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected fro N or C-R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  该发明涉及以下式（I）的新化合物：其中p为1、2或3；n为0、1、2或3；m为0、1、2或3；A为CRc、S、NRc或O，其中Rc为H或较低的烷基；X、Y和Z分别独立地选自N或C-R3，其中至少两个X、Y和Z为N；每个Ra独立地选自氢和较低烷基；每个Rb为氢或较低烷基；G为Ar基团或代表CN或未取代或取代的较低烷基；Ar为饱和或不饱和的环状基团，它是取代或未取代的，可能是五或六元单环或8、9、10、11或12元双环或三环环，并且可能包含0、1、2或3个从O、N和S中选取的杂原子；其中基团具有R1、R2、R3和R4的含义如此定义，以及其盐、酯、N-氧化物或前药；它们在蛋白激酶依赖性疾病治疗中的使用，它们在制造用于治疗所述疾病的药物组合物中的使用，二芳基脲衍生物在治疗所述疾病中的使用方法，包含这些新型二芳基脲衍生物的制药制剂，制造这些新型二芳基脲衍生物的方法，上述提及的新型二芳基脲衍生物的使用或使用方法，和/或这些新型二芳基脲衍生物用于治疗动物或人体的。
• Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors
  申请人：Bold Guido

  公开号：US20080039440A1

  公开（公告）日：2008-02-14

  The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CR c , S, NR c or O, where R c is H or lower alkyl; X, Y and Z are each independently selected from N or C—R 3 , wherein at least two of X, Y and Z are N; and each R a is independently selected from hydrogen and lower-alkyl; each R b is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R 1 , R 2 , R 3 and R 4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diary urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  本发明涉及公式I的新化合物：其中p为1、2或3；n为0、1、2或3；m为0、1、2或3；A为CRc、S、NRcor O，其中Rcis H或较低的烷基；X、Y和Z各自独立地选择自N或C—R3，其中至少有两个X、Y和Z为N；而每个Rais独立选择自氢和较低的烷基；每个Rbis氢或较低的烷基；G是Ar基团或表示CN或未取代或取代的较低烷基；Ar是饱和或不饱和的环状基团，其被取代或未取代，并且可能是五元或六元的单环或8、9、10、11或12元的双环或三环，并且可能包含0、1、2或3个从O、N和S中选择的杂原子；其中基团具有R1、R2、R3和R4的含义如本文所定义，其盐、酯、N-氧化物或前药；并且它们在蛋白激酶依赖性疾病的治疗中的使用，它们在制造用于治疗该等疾病的药物组合物中的使用，二苯基脲衍生物在治疗该等疾病中的使用方法，包括这些新的二苯基脲衍生物的制药制剂，制造新的二苯基脲衍生物的方法，上述提到的新的二苯基脲衍生物的使用或使用方法，以及/或这些新的二苯基脲衍生物用于治疗动物或人体。
• US7855215B2
  申请人：——

  公开号：US7855215B2

  公开（公告）日：2010-12-21
• Cyclic diaryl ureas suitable as tyrosine kinase inhibitors
  申请人：Novartis AG

  公开号：US07855215B2

  公开（公告）日：2010-12-21

  The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected from N or C—R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diary urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  本发明涉及一种新型化合物，其化学式为I：其中，p为1、2或3；n为0、1、2或3；m为0、1、2或3；A为CRc、S、NRc或O，其中Rc为H或低级烷基；X、Y和Z分别独立地选自N或C—R3，其中至少两个为N；每个Ra独立地选自氢和低级烷基；每个Rb为氢或低级烷基；G为Ar基团或表示CN或未取代或取代的低级烷基；Ar为饱和或不饱和的环状基团，其取代或未取代，可能是五元或六元单环或8、9、10、11或12元的双环或三环，并且可能包含0、1、2或3个来自O、N和S的杂原子；所述基团R1、R2、R3和R4的含义如本文所定义，以及其盐、酯、N-氧化物或前药；以及它们在蛋白激酶依赖性疾病的治疗中的应用，它们在制造用于治疗该疾病的药物组合物中的应用，以及使用二苯基脲衍生物治疗该疾病的方法，包括这些新型二苯基脲衍生物的制药制剂，制造这些新型二苯基脲衍生物的方法，上述新型二苯基脲衍生物的使用或使用方法，和/或这些新型二苯基脲衍生物用于治疗动物或人体的用途。